Selected research
Industry Research
Idiopathic Hypersomnia Treatment Industry Research Report 2026
Market perspective
The global Idiopathic Hypersomnia Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Idiopathic Hypersomnia Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Idiopathic Hypersomnia Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Idiopathic Hypersomnia Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Idiopathic Hypersomnia Treatment include Avadel Pharmaceuticals, BIOPROJET, Drive DeVilbiss Healthcare, Fisher and Paykel Healthcare, Jazz Pharmaceuticals, Theranexus, GlaxoSmithKline, Pfizer and Merck, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Idiopathic Hypersomnia Treatment market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Idiopathic Hypersomnia Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Idiopathic Hypersomnia Treatment Market by Company
Avadel Pharmaceuticals
BIOPROJET
Drive DeVilbiss Healthcare
Fisher and Paykel Healthcare
Jazz Pharmaceuticals
Theranexus
GlaxoSmithKline
Pfizer
Merck
Teva Pharmaceutical Industries
Takeda Pharmaceutical
Idiopathic Hypersomnia Treatment Segment by Type
Stimulant Medications
Non-Stimulant Wake-Promoting Medications
Sodium Oxybate
Idiopathic Hypersomnia Treatment Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Idiopathic Hypersomnia Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Hypersomnia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Hypersomnia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Hypersomnia Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Idiopathic Hypersomnia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Stimulant Medications
- Non-Stimulant Wake-Promoting Medications
- Sodium Oxybate
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Avadel Pharmaceuticals
- BIOPROJET
- Drive DeVilbiss Healthcare
- Fisher and Paykel Healthcare
- Jazz Pharmaceuticals
- Theranexus
- GlaxoSmithKline
- Pfizer
- Merck
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Idiopathic Hypersomnia Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Stimulant Medications
- 2.2.3 Non-Stimulant Wake-Promoting Medications
- 2.2.4 Sodium Oxybate
- 2.3 Idiopathic Hypersomnia Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 Idiopathic Hypersomnia Treatment Breakdown Data by Type
- 3.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2027-2032)
4 Idiopathic Hypersomnia Treatment Breakdown Data by Application
- 4.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2021-2032)
- 5.2 Global Idiopathic Hypersomnia Treatment Growth Trends by Region
- 5.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Idiopathic Hypersomnia Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Idiopathic Hypersomnia Treatment Market Dynamics
- 5.3.1 Idiopathic Hypersomnia Treatment Industry Trends
- 5.3.2 Idiopathic Hypersomnia Treatment Market Drivers
- 5.3.3 Idiopathic Hypersomnia Treatment Market Challenges
- 5.3.4 Idiopathic Hypersomnia Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue
- 6.1.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Idiopathic Hypersomnia Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Idiopathic Hypersomnia Treatment Head Office and Area Served
- 6.4 Global Idiopathic Hypersomnia Treatment Players, Product Type & Application
- 6.5 Global Idiopathic Hypersomnia Treatment Manufacturers Established Date
- 6.6 Global Idiopathic Hypersomnia Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Idiopathic Hypersomnia Treatment Market Size (2021-2032)
- 7.2 North America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Idiopathic Hypersomnia Treatment Market Size by Country (2021-2026)
- 7.4 North America Idiopathic Hypersomnia Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Idiopathic Hypersomnia Treatment Market Size (2021-2032)
- 8.2 Europe Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2021-2026)
- 8.4 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Idiopathic Hypersomnia Treatment Market Size (2021-2032)
- 10.2 South America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Idiopathic Hypersomnia Treatment Market Size by Country (2021-2026)
- 10.4 South America Idiopathic Hypersomnia Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Avadel Pharmaceuticals
- 12.1.1 Avadel Pharmaceuticals Company Information
- 12.1.2 Avadel Pharmaceuticals Business Overview
- 12.1.3 Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.1.4 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio
- 12.1.5 Avadel Pharmaceuticals Recent Developments
- 12.2 BIOPROJET
- 12.2.1 BIOPROJET Company Information
- 12.2.2 BIOPROJET Business Overview
- 12.2.3 BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.2.4 BIOPROJET Idiopathic Hypersomnia Treatment Product Portfolio
- 12.2.5 BIOPROJET Recent Developments
- 12.3 Drive DeVilbiss Healthcare
- 12.3.1 Drive DeVilbiss Healthcare Company Information
- 12.3.2 Drive DeVilbiss Healthcare Business Overview
- 12.3.3 Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.3.4 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product Portfolio
- 12.3.5 Drive DeVilbiss Healthcare Recent Developments
- 12.4 Fisher and Paykel Healthcare
- 12.4.1 Fisher and Paykel Healthcare Company Information
- 12.4.2 Fisher and Paykel Healthcare Business Overview
- 12.4.3 Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.4.4 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product Portfolio
- 12.4.5 Fisher and Paykel Healthcare Recent Developments
- 12.5 Jazz Pharmaceuticals
- 12.5.1 Jazz Pharmaceuticals Company Information
- 12.5.2 Jazz Pharmaceuticals Business Overview
- 12.5.3 Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.5.4 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio
- 12.5.5 Jazz Pharmaceuticals Recent Developments
- 12.6 Theranexus
- 12.6.1 Theranexus Company Information
- 12.6.2 Theranexus Business Overview
- 12.6.3 Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.6.4 Theranexus Idiopathic Hypersomnia Treatment Product Portfolio
- 12.6.5 Theranexus Recent Developments
- 12.7 GlaxoSmithKline
- 12.7.1 GlaxoSmithKline Company Information
- 12.7.2 GlaxoSmithKline Business Overview
- 12.7.3 GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.7.4 GlaxoSmithKline Idiopathic Hypersomnia Treatment Product Portfolio
- 12.7.5 GlaxoSmithKline Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.8.4 Pfizer Idiopathic Hypersomnia Treatment Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Merck
- 12.9.1 Merck Company Information
- 12.9.2 Merck Business Overview
- 12.9.3 Merck Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.9.4 Merck Idiopathic Hypersomnia Treatment Product Portfolio
- 12.9.5 Merck Recent Developments
- 12.10 Teva Pharmaceutical Industries
- 12.10.1 Teva Pharmaceutical Industries Company Information
- 12.10.2 Teva Pharmaceutical Industries Business Overview
- 12.10.3 Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.10.4 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product Portfolio
- 12.10.5 Teva Pharmaceutical Industries Recent Developments
- 12.11 Takeda Pharmaceutical
- 12.11.1 Takeda Pharmaceutical Company Information
- 12.11.2 Takeda Pharmaceutical Business Overview
- 12.11.3 Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2021-2026)
- 12.11.4 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product Portfolio
- 12.11.5 Takeda Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst